Christopher S. Hourigan

Hematology
401 N Broadway St
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 155 publications

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Journal: The New England journal of medicine
Published: September 02, 2026

Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?

Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?

Journal: Seminars in hematology
Published: March 16, 2026

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.

Journal: Haematologica
Published: February 20, 2026

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing.

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing.

Journal: Haematologica
Published: February 12, 2026

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia.

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia.

Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

Journal: Blood
Published: February 04, 2026

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

Journal: Blood
Published: February 04, 2026

Genomics of Acute Myeloid Leukemia at Diagnosis and Remission.

Genomics of Acute Myeloid Leukemia at Diagnosis and Remission.

Journal: medRxiv : the preprint server for health sciences
Published: December 17, 2025

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Journal: HemaSphere
Published: October 21, 2025

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Journal: Blood
Published: September 16, 2025

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

Journal: Blood
Published: September 16, 2025

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia.

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia.

Journal: Bone marrow transplantation
Published: August 07, 2025
Showing 1-12 of 155

Last Updated: 09/26/2026